| Price | $9.74 |
| Year Range | $9.74 – $24.56 |
| Market Cap | $863M |
| Industry | Biotechnology |
What Is Monte Rosa Therapeutics’s AI Stock Analysis?
Monte Rosa Therapeutics’s AI stock analysis on AltIndex combines the company’s fundamentals, price technicals and 25+ alternative data signals — like hiring, web traffic, app downloads and online sentiment — into a single AI Score from 0 to 100 and a plain-English Buy, Hold or Sell read. Unlike a traditional analyst rating that updates a few times a year, the AI Score refreshes as new data arrives, so it tracks Monte Rosa Therapeutics’s momentum in near-real time.
Monte Rosa Therapeutics (GLUE) has an AltIndex AI Score of 52/100, currently a Hold signal. The AI Score distills Monte Rosa Therapeutics's fundamentals, price technicals and 25+ alternative data signals into a single 0–100 rating, so a rising score reflects strengthening data across the board and a falling score the opposite.
Monte Rosa Therapeutics’s Full AI Analysis
Keep reading AltIndex’s full AI analysis of Monte Rosa Therapeutics — the fundamental, technical and alternative-data breakdown and the recommendation.
Sign up to read the full analysisWhat’s Driving GLUE’s AI Score?
Fundamentals
Revenue for the last quarter was $9M. This is an increase of 113.02% compared to the quarter before it, which is a positive sign of growth. However, compared to the same quarter last year, there is a decrease of 61.33%, which may be a cause for concern. Net income for the last quarter was $-43M. This is an increase of -2.49% compared to the quarter before it, which is a positive sign of growth. However, compared to the same quarter last year, there is a decrease of 252.96%, which may be a cause for concern. Ebitda for the last quarter was $-41M. This is an increase of -2.70% compared to the quarter before it, which is a positive sign of growth. However, compared to the same quarter last year, there is a decrease of 360.09%, which may be a cause for concern.
See Monte Rosa Therapeutics’s earnings and insider transactions.
Technicals
Today's stock price is $9.74. This represents a decrease of 22.70% compared to a month ago, which may be concerning in the short-term. However, compared to a year ago, there is a decrease of 3.08%, which could be a cause for long-term concern. The trend is bearish. The current SMA10 is $10.15, which is lower than the previous SMA10 of $10.16. This suggests a potential downward trend in price movement. The RSI is 81, indicating a potentially overbought (bearish) condition.
See the full technical analysis and price prediction.
Frequently Asked Questions: Monte Rosa Therapeutics AI Stock Analysis
Monte Rosa Therapeutics's AltIndex AI Score is 52/100, currently a Hold signal. The AI Score blends fundamentals, technicals and 25+ alternative data signals into a single rating from 0 to 100.
AltIndex's AI Score model rates Monte Rosa Therapeutics a Hold (52/100). This is a data-driven signal, not investment advice — review the breakdown above and combine it with your own research.
The AI Score is generated from fundamental data (earnings, valuation), technical indicators (price trend and momentum), and alternative data signals such as hiring, web traffic, app downloads and sentiment. AltIndex weighs these into a single 0-100 score; the exact weighting is proprietary.
AltIndex generates a complete written AI analysis of Monte Rosa Therapeutics — company overview, fundamentals, technicals and alternative data, with a recommendation. See the GLUE AI Score or sign up to read the full thesis.
